Advanced Biomed Inc

Análisis de la acción Advanced Biomed Inc (ADVB)

$5.140

-0.020 (-0.39%)Al cierre

Loading chart…
Máximo
5.550
Apertura
5.260
Precio medio ponderado por volumen
5.28
Volumen
13.72K
Capitalización
—
Mínimo
5.140
Importe
72.40K
EV/EBITDA, TTM
0.00

Advanced Biomed Inc. is a holding company that operates, through its subsidiary, Advanced Biomed Inc. (Taiwan). The Company is engaged in the provision of assay products and services for cancer patients. These services include early screening and detection, diagnosis and staging, and treatment of cancer through the detection of circulating tumor cells and related tumor markers. It has developed a microfluidic technology platform to integrate research and development, design, and manufacture of biochips and microfluidic chips. The platform combines its patented chip technology and will enable localized operations of a variety of microfluidic chips, biosensors made by semiconductor fabrication technology, and integrated application patented technology. The Company offers devices, such as A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre-Chip and AC-1000 CTC Enrichment Chip and A+CellScan Chip.

Análisis de IA of Advanced Biomed Inc (ADVB)

Vender

Advanced Biomed Inc. is not a good buy right now due to its extremely low RSI of 19.002, indicating oversold conditions, and a significant recent decline of 21.10% over the last five days. The stock is currently trading at $5.31, which is far below its recent highs of $20.87, suggesting a volatile and risky investment. The company also reported a negative net income of -488,942 USD in Q3 2026, which raises concerns about its financial stability.

Métricas de valoración

El PER previsto actual de Advanced Biomed Inc (ADVB) es 0.00, frente a su media de 5 años de 0.00.

PER previsto

Muy infravalorado
Media 5A P/E
0.00
P/E actual
0.00
Sobrevalorada
0.00
Infravalorada
0.00

EV/EBITDA previsto

Muy infravalorado
Media 5A EV/EBITDA
0.00
EV/EBITDA actual
0.00
Sobrevalorada
0.00
Infravalorada
0.00

Precio/ventas previsto

Muy infravalorado
Media 5A P/S
0.00
P/S actual
0.00
Sobrevalorada
0.00
Infravalorada
0.00

Escenarios de precio de Alphio AI para ADVB

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%ADVB

$0.72

Precio del escenario

B

Base

Base · 50%ADVB

$0.61

Precio del escenario

B

Bajista

Bajista · 25%ADVB

$0.56

Precio del escenario

Cronología de eventos

2026-07-30 (ET)

10:00:00

Advanced Biomed Inc Trading Halted Due to Volatility

2026-07-27 (ET)

10:00:00

Advanced Biomed Inc Trading Halted Due to Volatility

2026-07-24 (ET)

11:00:00

Advanced Biomed Inc Trading Halted Due to Volatility

2026-07-23 (ET)

10:30:00

Advanced Biomed Inc Trading Halted Due to Volatility

2026-07-22 (ET)

10:00:00

Advanced Biomed Inc Trading Halted Due to Volatility

Noticias

Preguntas frecuentes sobre ADVB, respondidas por Alphio AI

Advanced Biomed Inc. is a holding company that operates, through its subsidiary, Advanced Biomed Inc. (Taiwan). The Company is engaged in the provision of assay products and services for cancer patients. These services include early screening and detection, diagnosis and staging, and treatment of cancer through the detection of circulating tumor cells and related tumor markers. It has developed a microfluidic technology platform to integrate research and development, design, and manufacture of biochips and microfluidic chips. The platform combines its patented chip technology and will enable localized operations of a variety of microfluidic chips, biosensors made by semiconductor fabrication technology, and integrated application patented technology. The Company offers devices, such as A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre-Chip and AC-1000 CTC Enrichment Chip and A+CellScan Chip. It operates in the Healthcare sector.

Advanced Biomed Inc. is not a good buy right now due to its extremely low RSI of 19.002, indicating oversold conditions, and a significant recent decline of 21.10% over the last five days. The stock is currently trading at $5.31, which is far below its recent highs of $20.87, suggesting a volatile and risky investment. The company also reported a negative net income of -488,942 USD in Q3 2026, which raises concerns about its financial stability.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar